Search

It’s been another tumultuous week in the market, though much of that occurred on Monday’s 12%-ish plunge in the major indexes.

The market has been extended and vulnerable to a sharp pullback for the past couple of weeks, and last night’s surprise attacks overseas provided a reason for the sellers to do some work—this morning, the major indexes and most stocks are taking a hit.

It’s been another relatively quiet week for the major indexes, with most up in the 0.5% range, though the Nasdaq has outperformed, rising around 1.7% on the week as of this morning.

As earnings season has picked up, we’ve been pleased to see mostly positive reactions across the market and individual stocks, including some potential fresh leaders.

Tuesday’s better-than-expected GDP numbers should be a nice boost to growth stocks, even if it all but assures another interest rate hike later this month.

The broad market finally firmed up last week. After closing below their 50-day lines the previous Friday, the Dow, S&P 500 and Nasdaq all found support early last week, then rebounded strongly at the end of the week. However, while the market is firming, four of our holdings stumbled on earnings last week.

Stocks started off somewhat promisingly this week, with a huge plunge Monday morning followed by a massive reversal that afternoon. But stocks haven’t been able to build on that at all, with numerous intraday rally failures and with some indexes already probing lower lows, especially broader and growth-oriented indexes and funds.

Yesterday was another extremely volatile day in the stock market for options traders. Being patient is challenging for many traders, and especially options traders. We’re often looking for the next home run. However, in this environment, patience is key.

From Top Stock Insights: “Currently, the only way to provide signals to consumers on the ground is to use decades old cell towers. Not only are those towers old and decrepit, they are ugly,...

Donald Trump pulled the U.S. out of the Paris climate agreement, and that’s ostensibly bad news for Tesla. But will it actually impact TSLA stock?

Once a high riser, the IHE biotech ETF has been stuck in the mud for two years. But that doesn’t mean you should tune out the biopharma industry as a whole.

It’s been a solid week in the market, with the major indexes posting solid gains through Thursday. Interestingly, we came close to a legitimate blastoff signal yesterday (the Three Day Thrust), and if we see another 1% gain in the S&P 500 today, it would be a super bullish signal. That said, the market is indicated to open lower this morning, though the damage doesn’t seem too bad.

Whether it was a meltdown in Chinese stocks due to regulatory actions, fears of renewed virus restrictions (and mask mandates) or inflation jitters, the market is getting hit sharply today, and growth stocks are going along for the ride—as of 1 p.m. ET, the Dow is off 195 points, while the Nasdaq is down 291 points and growth-y indexes are down 3%-plus. We’re not going to draw a massive conclusion from one day of trading, especially as it comes on the heels of what was a darn good few days for growth stocks following last Monday’s shakeout. But it is a sign that the endless choppy phase might not be in the rearview mirror.

Karyopharm (KPTI) pre-announced Q4 2020 results yesterday morning and I watched the stock, which was weak (closed down 8%) throughout the day as I pondered the results. I’ll get to my thoughts in a minute. First, the numbers.

This portfolio stock reported preliminary Q4 revenue results a while back that were better than expected, and last night in the official earnings release and on the conference call management announced that profitability was also way above expectations.

Tyler updates us on two more stocks that reported earnings recently.

It looks like we’ll be ending this week on a big down note as stocks are heading south once again. The culprit is no surprise; concern that this virus will spark at least a short-term economic downturn.